[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:acute-lymphoblastic-leukemia:cd19-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Acute Lymphoblastic Leukemia","CD19 Gene",16,[8,16,23,29,34,40,46,53,60,66,72,78,84,90,97,104],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07400029","A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia",[12],"Phase 2","RECRUITING","2026-08-26T02:17:17.791881Z","2026-07-05T05:32:16.679314Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06408194","Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies",[20],"Phase 1","2026-08-26T02:16:54.876240Z","2026-05-05T02:43:29.029325Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07257419","CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+\u002FCD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed\u002FRefractory CD19+ ALL and Lymphoma",[20],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:27.676036Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":14,"content_modified":33},"NCT06847269","CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia",[12],"2026-05-05T02:43:27.418413Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":38,"content_modified":39},"NCT06777979","CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia",[20],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:26.924544Z",{"nct_id":41,"title":42,"phases":43,"status":13,"updated_at":44,"content_modified":45},"NCT06287528","A Study of 19-28z\u002FIL-18 in People With Acute Lymphoblastic Leukemia (ALL)",[20],"2026-08-26T02:18:49.989941Z","2026-05-05T02:35:31.697561Z",{"nct_id":47,"title":48,"phases":49,"status":13,"updated_at":51,"content_modified":52},"NCT06735690","Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia",[50],"Early Phase 1","2026-08-26T02:16:04.914942Z","2026-05-05T02:35:31.635862Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":58,"content_modified":59},"NCT06364423","Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias",[57],"Phase 1\u002FPhase 2","2026-08-26T02:18:24.494016Z","2026-07-05T05:32:16.752213Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT05848687","TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II",[57],"2026-08-26T02:16:24.970704Z","2026-05-05T02:43:29.336397Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT01853631","Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)",[20],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:28.649787Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06227026","Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed\u002FRefractory CD19+ Malignancies",[20],"2026-08-26T02:15:11.740957Z","2026-04-29T02:57:57.116949Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT07052370","TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies",[20],"2026-08-26T02:17:52.450442Z","2026-05-05T02:43:29.201965Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT05418088","Genetically Engineered Cells (Anti-CD19\u002FCD20\u002FCD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies",[20],"2026-08-26T02:16:49.565137Z","2026-05-05T02:43:27.982458Z",{"nct_id":91,"title":92,"phases":93,"status":94,"updated_at":95,"content_modified":96},"NCT07614022","A Phase I Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive ALL",[20],"NOT_YET_RECRUITING","2026-08-26T02:16:39.977107Z","2026-05-29T15:36:40.232902Z",{"nct_id":98,"title":99,"phases":100,"status":101,"updated_at":102,"content_modified":103},"NCT06773936","Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:15:24.145250Z","2026-06-16T05:54:07.771453Z",{"nct_id":105,"title":106,"phases":107,"status":101,"updated_at":108,"content_modified":109},"NCT03226704","Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing",[],"2026-08-26T02:19:13.549512Z","2026-06-16T05:54:07.964568Z"]